>
Switch to:

PTC Therapeutics Net Change in Cash

: $-2.5 Mil (TTM As of Mar. 2022)
View and export this data going back to 2013. Start your Free Trial

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

PTC Therapeutics's Net Change in Cash for the three months ended in Mar. 2022 was $-45.5 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2022 was $-2.5 Mil.

PTC Therapeutics Net Change in Cash Historical Data

The historical data trend for PTC Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PTC Therapeutics Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Net Change in Cash
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.47 57.71 126.03 -79.22 -19.09

PTC Therapeutics Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Net Change in Cash Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -62.18 30.72 12.47 -0.10 -45.54

PTC Therapeutics Net Change in Cash Calculation

PTC Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2021 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-251.332+219.182+20.877+-7.821
=-19.1

PTC Therapeutics's Net Change in Cash for the quarter that ended in Mar. 2022

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-97.404+49.043+1.168+1.653
=-45.5

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PTC Therapeutics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

PTC Therapeutics Business Description

PTC Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Comparable Companies
NAS:ARVN NAS:FOLD NAS:FATE NAS:INSM NAS:CORT NAS:ABCL NAS:BEAM NAS:EQRX NAS:IOVA NAS:SAGE OCSE:NOVO B ASX:CSL NAS:REGN NAS:VRTX NAS:MRNA XKRX:207940 NAS:BNTX HKSE:02269 NAS:SGEN SZSE:300122
Traded in Other Exchanges
P91:Germany P91:Germany
Address
100 Corporate Court, South Plainfield, NJ, USA, 07080
Website
https://www.ptcbio.com
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Executives
Southwell David P director C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE LEXINGTON MA 02421
Jacobson Allan Steven director PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Peltz Stuart Walter director, officer: Chief Executive Officer PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Utter Christine Marie officer: SVP, Finance & CAO C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Boulding Mark Elliott officer: Exec. VP and CLO C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Hill Emily Luisa officer: Chief Financial Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Svoronos Dawn director C/O MEDIVATION, INC. 525 MARKET ST., 36TH FLOOR SAN FRANCISCO CA 94105
Pauwels Eric officer: Chief Business Officer 550 HILLS DRIVE BEDMINSTER NJ 07921
Klein Matthew B. officer: Chief Development Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Schmertzler Michael director 1300 VALLEY ROAD NEW CANAAN CT 06840
Souza Marcio officer: Chief Operating Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Almstead Neil Gregory officer: Chief Technical Ops Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Reeve Emma director C/O PAREXEL INTERNATIONAL CORPORATION 195 WEST STREET WALTHAM MA 02451
Steele Glenn Jr Md Phd director 250 TECHNOLOGY PARK LAKE MARY FL 32746-6232
Zeldis Jerome B director 8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258

PTC Therapeutics Headlines

From GuruFocus

PTC Therapeutics to Present New Data at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference

By PRNewswire 03-11-2022

FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy

By PRNewswire 01-25-2022

PTC Therapeutics Recognizes 2021 STRIVE Awards Recipients for Initiatives Supporting Duchenne Patient Community

By PRNewswire 09-07-2021

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By PRNewswire 09-29-2021

PTC Announces Expansion of Translarna™ Label to Include Ambulatory Patients as Young as 2 Years Old in Brazil

By PRNewswire 10-25-2021

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By PRNewswire 01-13-2022

PTC Therapeutics Celebrates Opening of Gene Therapy Manufacturing Facility

By PRNewswire 10-14-2021

PTC Therapeutics Announces Waylivra™ Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome

By PRNewswire 08-23-2021

Targeting the Putamen with Gene Therapy Leads to Sustained Improvements in Motor and Non-Motor Functions in Children with AADC Deficiency

By PRNewswire 08-23-2021

Results Show Long-Lasting and Holistic Improvements in Children with AADC Deficiency Treated with PTC-AADC Gene Therapy

By PRNewswire 09-29-2021

Other Sources

PTC Therapeutics Gets First Milestone Payment for SMA Drug

By Zacks 2020-08-27

Roche's (RHHBY) SMA Treatment Evrysdi Secures EC Approval

By Zacks 2021-03-30

$EDIT $PTCT - Editas Medicine Review Plus Now - Better Choice Of PTC Therapeutics. Editas Medicine Review Plus Now Better Choice Of Ptc Therapeutics

By Seekingalpha 2020-08-28

Earnings Preview: PTC Therapeutics (PTCT) Q3 Earnings Expected to Decline

By Zacks 2021-10-21

PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates

By Zacks 2021-05-04

PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates

By Zacks 2021-10-28

PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates

By Zacks 2021-02-25

PTC Therapeutics (PTCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

By Zacks 2021-02-18

PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates

By Zacks 2022-02-22

PTC Therapeutics' Application for SMA Drug Accepted by EU

By Zacks 2020-08-18

$PTCT - PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q2 2021 Results - Earnings Call Transcript.…

By Seekingalpha 2021-07-29

PTC Therapeutics (PTCT) Soars 11.1%: Is Further Upside Left in the Stock?

By Zacks 2022-04-04

United Therapeutics (UTHR) Moves 3.1% Higher: Will This Strength Last?

By Zacks 2022-03-14

$PTCT - PTC Therapeutics (PTCT) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference.…

By Seekingalpha 2022-01-12

$PTCT - PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q4 2021 Results - Earnings Call Transcript.…

By Seekingalpha 2022-02-23

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)